These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37821012)

  • 1. Kiwi-derived extracellular vesicles for oral delivery of sorafenib.
    Fang Z; Song M; Lai K; Cui M; Yin M; Liu K
    Eur J Pharm Sci; 2023 Dec; 191():106604. PubMed ID: 37821012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
    Wu B; Li A; Zhang Y; Liu X; Zhou S; Gan H; Cai S; Liang Y; Tang X
    Expert Opin Drug Deliv; 2020 Apr; 17(4):573-587. PubMed ID: 32056461
    [No Abstract]   [Full Text] [Related]  

  • 3. A polymeric nanoformulation improves the bioavailability and efficacy of sorafenib for hepatocellular carcinoma therapy.
    Chen Y; Li JX; Shu N; Zheng SJ; Ma M; Zhao ZB; Cao ZT; Zhou Q; Du JZ; Wang J
    Biomater Sci; 2021 Apr; 9(7):2508-2518. PubMed ID: 33459733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plant-derived extracellular vesicles as oral drug delivery carriers.
    Fang Z; Liu K
    J Control Release; 2022 Oct; 350():389-400. PubMed ID: 36037973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
    Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
    Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells.
    He C; Jaffar Ali D; Qi Y; Li Y; Sun B; Liu R; Sun B; Xiao Z
    J Nanobiotechnology; 2023 May; 21(1):154. PubMed ID: 37202772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy.
    Cao W; Liu X; Zhang Y; Li A; Xie Y; Zhou S; Song L; Xu R; Ma Y; Cai S; Tang X
    Biomed Res Int; 2021; 2021():5556306. PubMed ID: 33987439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracellular vesicles derived from cancer-associated fibroblasts carry tumor-promotive microRNA-1228-3p to enhance the resistance of hepatocellular carcinoma cells to sorafenib.
    Zhang Y; Pan Q; Shao Z
    Hum Cell; 2023 Jan; 36(1):296-311. PubMed ID: 36424471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model.
    Yu XN; Deng Y; Zhang GC; Liu J; Liu TT; Dong L; Zhu CF; Shen XZ; Li YH; Zhu JM
    ACS Appl Mater Interfaces; 2020 Apr; 12(15):17193-17206. PubMed ID: 32207914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
    Li Y; Wei J; Wei Y; Cheng L; Guo B; Meng F; Li F; Zhong Z
    Biomacromolecules; 2020 Feb; 21(2):716-724. PubMed ID: 31809037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a co-target for enhancing efficacy of sorafenib in HCC through a quantitative modeling approach.
    Mishra M; Jayal P; Karande AA; Chandra N
    FEBS J; 2018 Nov; 285(21):3977-3992. PubMed ID: 30136368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
    Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
    J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.
    Kong FH; Ye QF; Miao XY; Liu X; Huang SQ; Xiong L; Wen Y; Zhang ZJ
    Theranostics; 2021; 11(11):5464-5490. PubMed ID: 33859758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel delivery of sorafenib by natural killer cell-derived exosomes-enhanced apoptosis in triple-negative breast cancer.
    Hashemi ZS; Ghavami M; Kiaie SH; Mohammadi F; Barough MS; Khalili S; Hosseini-Farjam Z; Mossahebi-Mohammadi M; Sheidary A; Ghavamzadeh A; Forooshani RS
    Nanomedicine (Lond); 2023 Feb; 18(5):437-453. PubMed ID: 37199259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Effect of Sorafenib-Loaded TPGS-
    Tang X; Lyu Y; Xie D; Li A; Liang Y; Zheng D
    J Biomed Nanotechnol; 2018 Feb; 14(2):396-403. PubMed ID: 31352936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
    Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
    J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomal MiR-744 Inhibits Proliferation and Sorafenib Chemoresistance in Hepatocellular Carcinoma by Targeting PAX2.
    Wang G; Zhao W; Wang H; Qiu G; Jiang Z; Wei G; Li X
    Med Sci Monit; 2019 Sep; 25():7209-7217. PubMed ID: 31553714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
    Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.